Many of these polymorphisms do not actually change the CTLA-4 amino acid sequence, but can modify the affinity for the CTLA-4 mAb, increasing the risk of occurrence of immunotherapy-induced autoimmune disorders [48]. Here, CTLA4 is linked to autoimmune disease.